Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.

Volta M, Mabrouk OS, Bido S, Marti M, Morari M.

J Neurochem. 2010 Dec;115(6):1543-55. doi: 10.1111/j.1471-4159.2010.07061.x. Epub 2010 Nov 11.

3.

Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.

Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M.

J Neurosci. 2004 Jul 28;24(30):6659-66.

4.
6.

Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.

Volta M, Viaro R, Trapella C, Marti M, Morari M.

Exp Neurol. 2011 Mar;228(1):126-37. doi: 10.1016/j.expneurol.2010.12.024. Epub 2011 Jan 6.

PMID:
21215744
7.

Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.

Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M.

J Neurosci. 2014 Sep 24;34(39):12953-62. doi: 10.1523/JNEUROSCI.4677-13.2014.

8.
9.

Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures.

Bregola G, Zucchini S, Rodi D, Binaschi A, D'Addario C, Landuzzi D, Reinscheid R, Candeletti S, Romualdi P, Simonato M.

J Neurosci. 2002 Nov 15;22(22):10030-8.

10.

Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.

Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candeletti S, Simonato M, Cox BM, Morari M.

J Neurosci. 2005 Oct 19;25(42):9591-601.

11.

Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance.

Chung S, Pohl S, Zeng J, Civelli O, Reinscheid RK.

J Pharmacol Exp Ther. 2006 Jul;318(1):262-7. Epub 2006 Apr 4.

12.

Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).

Volta M, Marti M, McDonald J, Molinari S, Camarda V, Pelà M, Trapella C, Morari M.

Peptides. 2010 Jun;31(6):1194-204. doi: 10.1016/j.peptides.2010.03.015. Epub 2010 Mar 20.

PMID:
20307605
13.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M.

Br J Pharmacol. 2013 Feb;168(4):863-79. doi: 10.1111/j.1476-5381.2012.02219.x.

14.

Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.

Neurobiol Dis. 2016 May;89:55-64. doi: 10.1016/j.nbd.2016.01.016. Epub 2016 Jan 22.

PMID:
26804029
15.

Cloning and characterization of the rhesus monkey nociceptin/orphanin FQ receptor.

Koga K, Ichikawa D, Nambu H, Azuma-Kanoh T, Sakai N, Takaki-Kawagoe H, Ozaki S, Ohta H.

Genes Genet Syst. 2009 Oct;84(5):319-25.

16.
17.

Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.

Viaro R, Calcagno M, Marti M, Borrelli E, Morari M.

Neuropharmacology. 2013 Sep;72:126-38. doi: 10.1016/j.neuropharm.2013.04.046. Epub 2013 May 3.

PMID:
23643745
18.

Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2009 Dec;331(3):946-53. doi: 10.1124/jpet.109.156711. Epub 2009 Aug 27.

19.

[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.

Carrà G, Rizzi A, Guerrini R, Barnes TA, McDonald J, Hebbes CP, Mela F, Kenigs VA, Marzola G, Rizzi D, Gavioli E, Zucchini S, Regoli D, Morari M, Salvadori S, Rowbotham DJ, Lambert DG, Kapusta DR, Calo' G.

J Pharmacol Exp Ther. 2005 Mar;312(3):1114-23. Epub 2004 Oct 27.

20.

Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.

Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, Barnes TA, Rizzi A, Trapella C, Fanton G, Morari M, Lambert DG, Regoli D, Calò G.

J Pharmacol Exp Ther. 2007 Jun;321(3):961-7. Epub 2007 Feb 28.

Supplemental Content

Support Center